Neoadjuvant therapy for early human epidermal growth factor receptor 2 positive breast cancer in China: A multicenter real-world study (CSBrS-015)

CONCLUSIONS: Patients in the trastuzumab+pertuzumab group had a higher pCR rate than those in the trastuzumab group, and the toxic side effects were tolerable.PMID:36535009 | DOI:10.1097/CM9.0000000000002197

Source: Chinese Medical Journal - December 19, 2022 Category: General Medicine Authors: Yuanjia Cheng Hongyu Xiang Ling Xin Xuening Duan Yinhua Liu Chinese Society of Breast Surgery (CSBrS), Chinese Society of Surgery of Chinese Medical Association Source Type: research